Long Term Barrett's Endoscopic Mucosal Resection Study

Barretts Esophagus Clinical Trial

— CBE  

Official title:

Long Term Outcomes of Patients Undergoing Endoscopic Resection of Barrett's Oesophagus (BO) With High Grade Dysplasia (HGD) and Early Adenocarcinoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02200250
• Other study ID #: HREC2013/10/6.2(3838)QA
• Status: Withdrawn
• Start date: October 1, 2021
• Est. completion date: October 2022

Study information

• Verified date: June 2023
• Source: Western Sydney Local Health District
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Analysis of long term outcomes of patients undergoing endoscopic mucosal resection for Barrett's oesophagus with high grade dysplasia and/or early intramucosal carcinoma (IMC).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2022
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• 18 years or over
• Have or have had Barrett's Oesophagus

Exclusion Criteria:

• Do not have Barrett's Oesophagus
• Have not had Barrett's Oesophagus resected at Westmead Hospital

Related Conditions & MeSH terms

• Barrett Esophagus
• Barretts Esophagus

Locations

Country	Name	City	State
Australia	Westmead Endoscopy Unit	Westmead	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Professor Michael Bourke

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reviewing patients symptoms following resection	Patients will be contacted via phone and will be required to answer questions over the phone. Health questionnaires may also be sent at the patients request to complete and post back.	up to 3 years